1. bookVolume 6 (2022): Issue 1 (January 2022)
Journal Details
License
Format
Journal
eISSN
2564-615X
First Published
30 Jan 2017
Publication timeframe
4 times per year
Languages
English
access type Open Access

SARS-CoV-2 Alpha Variant Infection of a Patient Immunized by Inactive Sinovac (CoronaVac) Vaccine

Published Online: 24 Jan 2022
Page range: 27 - 31
Journal Details
License
Format
Journal
eISSN
2564-615X
First Published
30 Jan 2017
Publication timeframe
4 times per year
Languages
English
Abstract

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in December 2019, and shortly after pandemic has been declared by the World Health Organization (WHO) due to its unstoppable global spread. Considerable amount of effort has beenput around the World in order to develop a safe and effective vaccine against SARS-CoV-2. Inactivated and RNA vaccines have already passed phase three studies showing sufficient efficacy and safety, respectively. Nowadays, there is a noticeable dominance of SARS-CoV-2 variants with various mutations over the wild type SARS-CoV-2. However, there is no report showing the efficacy of these vaccines on these variants. This case study describes a thirty-eight-year-old male reported to be infected with SARS-CoV-2 alpha variant following two doses of inactive CoronaVac administration with a protective level of SARS-CoV-2 specific antibodies. The variant analysis of the virus reported to be positive for N501Y mutation.This is the first case in the literature demonstrating that inactive SARS-CoV-2 vaccine might have a lower efficacy on alpha variant.

Keywords

1. World Health Organization. WHO Director-General’s opening remarks at the media briefing on COVID-19 - 11 April 2021. Geneva: World Health Organization; 2021. https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarksat-the-media-briefing-on-covid-19 Search in Google Scholar

2. Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med.2020; 383:2603–2615. Search in Google Scholar

3. Voysey M, Costa Clemens SA, Madhi SA, Weckx LY, FolegattiPM, et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK. Lancet. 2020; 397: 99–111.10.1016/S0140-6736(20)32661-1 Search in Google Scholar

4. Reuters. Sinopharm’s COVID-19 vaccine 79% effective, seeks approval in China. https://www.reuters.com/article/us-health-coronavirus-china-vaccine/sinopharms-covid-19-vaccine-79-effective-seeks-approval-in-china-idUSKBN2940C8. 2020. Search in Google Scholar

5. BBC. Sinovac: Brazil results show Chinese vaccine 50.4% effective. https://www.bbc.com/news/world-latin-america-55642648.2020 Search in Google Scholar

6. Krammer F. SARS-CoV-2 vaccines in development. Nature. 2020; 586:516-52710.1038/s41586-020-2798-332967006 Search in Google Scholar

7. A.A. North Cyprus completes 1st vaccination drive. https://www.aa.com.tr/en/europe/northern-cyprus-completes-1st-vaccination-drive/2119598 (2021) Search in Google Scholar

8. Liu Z, VanBlargan LA, Bloyet LM, Rothlauf PW, Chen RE, Stumpf S, Zhao H, Errico JM, Theel ES, Liebeskind MJ, Al-ford B, Buchser WJ, Ellebedy AH, Fremont DH, Diamond MS, Whelan SPJ. Identification of SARS-CoV-2 spike mutations that attenuate monoclonal and serum antibody neutralization. Cell Host Microbe. 2021 Mar 10;29(3):477-488.e4.10.1016/j.chom.2021.01.014783983733535027 Search in Google Scholar

9. Nelson G, Buzko O, Spilman P, Niazi K, Rabizadeh S, Soon-Shiong P. Molecular dynamic simulation reveals E484K mutation enhances spike RBD-ACE2 affinity and the combination of E484K, K417N and N501Y mutations (501Y.V2 variant) induces conformational change greater than N501Y mutant alone, potentially resulting in an escape mutant. BioxRviv preprint https://doi.org/10.1101/2021.01.13.426558.2021 Search in Google Scholar

10. Mahase E. Covid-19: Where are we on vaccines and variants? BMJ 2021;372:n597 https://doi.org/10.1136/bmj.n59710.1136/bmj.n59733653708 Search in Google Scholar

11. Beusekom MV. Pfizer, Moderna vaccines may be less effective against B1351 variant. 18 Feb 2021. Center for Infectious Disease Research and Policy, University of Minnesota. https://www.cidrap.umn.edu/news-perspective/2021/02/pfizer-moderna-vaccines-may-be-lesseffective-against-b1351-varian Search in Google Scholar

12. A novel SARS-CoV-2 variant of concern, B.1.526, identified in New York. https://www.medrxiv.org/content/10.1101/2021.02.23.21252259v1. Search in Google Scholar

13. Global Times. Half of Bulgaria’s regions report corona-virus variant first detected in Britain. https://www.global-times.cn/page/202103/1217786.shtml (9 March 2021) Search in Google Scholar

14. Roquebert B, Haim-Boukobza S, Trombert-Paolantoni S, Lecorche E, Verdurme L, Foulonge V, Burrel S, Alizon S, Sofonea MT. SARS-CoV-2 variants of concern are associated with lower RT-PCR amplification cycles between January and March 2021 in France. Int J of Inf Dis. 2021;113:12-1410.1016/j.ijid.2021.09.076848400434601145 Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo